SCHEMBL3828295

SCHEMBL3828295

Brc1nccc2ccncc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 1/20 0.44
DYRK1A Q13627 1/20 0.44
TNF P01375 2/20 0.41
AXL P30530 1/20 0.39
MAPK10 P53779 4/20 0.39
IMPDH2 P12268 1/20 0.38
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.37
HTT P42858 1/20 0.37
RAD52 P43351 1/20 0.37
CCNT1 O60563 1/20 0.37
PIM1 P11309 1/20 0.37
CDK9 P50750 1/20 0.37
HASPIN Q8TF76 1/20 0.37
MAOA P21397 2/20 0.35
HIPK2 Q9H2X6 1/20 0.35
CYP2A6 P11509 1/20 0.34
F12 P00748 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31401046 0.84 IMPDH2 (0.50) CLK1DYRK1AAXLIMPDH2PDE3B
SCHEMBL3386889 0.84 IMPDH2 (0.50) CLK1DYRK1AAXLIMPDH2PDE3B
SCHEMBL2984594 0.77 LMNA (0.47) CLK1DYRK1ATNFMAPK10IMPDH2
SCHEMBL3382695 0.76 AXL (0.47) CLK1DYRK1AAXLIMPDH2PDE3B
SCHEMBL672509 0.75 CLK1 (0.54) CLK1DYRK1ATNFMAPK10IMPDH2
SCHEMBL29569821 0.75 CLK1 (0.54) CLK1DYRK1ATNFMAPK10IMPDH2
SCHEMBL30100779 0.74 PLAU (0.56) KDM4EPOLBCYP2A6F12PLAU
SCHEMBL248635 0.74 PLAU (0.56) KDM4EPOLBCYP2A6F12PLAU
SCHEMBL7757453 0.73 CYP2A6 (0.59) CLK1DYRK1ATNFMAPK10PDE3B
SCHEMBL276690 0.73 CLK1 (0.44) CLK1DYRK1ATNFMAPK10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1999110-B1 PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES UCB PHARMA SA (BE) 2009-09-16 EP disclosed
US-20090221828-A1 Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives UCB PHARMA, S.A. (BE) 2009-09-03 US disclosed
EP-1999110-A2 PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES UCB Pharma, S.A. (BE) 2008-12-10 EP disclosed
WO-2007107345-A2 PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES UCB PHARMA, S.A. (BE) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221828-A1 Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives NPM1, XPO4, BRD7 CLK1 345/4885DYRK1A 1014/4885TNF 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.